Insulin

Inhaled insulin: make or break?

Inhaled insulin: make or break?

By Katrina Megget

Eli Lilly is remaining optimistic about its yet-to-be-approved
inhaled insulin despite the dramatic downfall of Pfizer's Exubera.
But is Exubera's fall from grace an indication of things to come
for inhaled diabetes treatments?

QDose closes in on Exubera

QDose closes in on Exubera

By Anna Lewcock

An improved inhalable insulin product developed by collaborating UK
and US firms has just completed a glucose clamp study in the US,
with results suggesting that the product could pose a significant
threat to Pfizer's Exubera...